Q-omics provides the consensus-scored PEX19 profile across patient tissues and cancer cell-line models. PEX19 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PEX19 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, PEX19 RNA expression shows 19,686 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where PEX19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX19 survival associations across molecular data types. PEX19 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX19 RNA expression–survival associations across cancer types. High PEX19 expression shows unfavorable associations in UVM, ACC, LUSC and ESCA, but favorable associations in KIRC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PEX19 RNA expression.
This table summarizes PEX19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PEX19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX19 shows lower tumor expression in COAD, KICH, KIRC, BRCA and LUSC and higher tumor expression in LIHC. The COAD box plot shows higher PEX19 RNA expression in normal versus tumor tissue (log2 FC = −0.361, t-test p < 0.001).
This table shows molecular features associated with PEX19 in patient tissues and cancer cell lines. In patient samples, PEX19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
